Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
Ocular Graft Versus Host Disease (OGVHD) is a serious potential complication of allogeneic
bone marrow transplants. The usual treatment is topical cyclosporine but when the treatment
is initiated the damage to the lacrimal glands has already taken place.
The present study aims to prevent OGVHD in reduced-intensity allogeneic hematopoietic
transplants by using topical cyclosporine immediately after the engraftment has been achieved